Skip to main content

Inflammatory Diseases

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD6793Phase 11 trial
Active Trials
NCT05662033Completed93Est. Oct 2024
Ionis Pharmaceuticals
1 program
ISIS 353512PHASE_11 trial
Active Trials
NCT00734240Completed103Est. Mar 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AstraZenecaAZD6793
Ionis PharmaceuticalsISIS 353512

Clinical Trials (2)

Total enrollment: 196 patients across 2 trials

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oral AZD6793 in Healthy and Chronic Obstructive Pulmonary Disease Participants, to Assess the Relative Oral Bioavailability Between Two Formulations, and the Food Effect on the PK of AZD6793 Compared to Fasting State.

Start: Dec 2022Est. completion: Oct 202493 patients
Phase 1Completed

Safety and Tolerability of Single and Multiple Doses of ISIS 353512 in Healthy Volunteers

Start: Jul 2008Est. completion: Mar 2010103 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.